Abstract

Mechanism-based inhibition of proteinases by serpins involves enzyme acylation and fast insertion of the reactive center loop (RCL) into the central beta-sheet of the serpin, resulting in mechanical inactivation of the proteinase. We examined the effects of ligands specific to alpha-helix F (alphaHF) of plasminogen activator inhibitor-1 (PAI-1) on the stoichiometry of inhibition (SI) and limiting rate constant (k(lim)) of RCL insertion for reactions with beta-trypsin, tissue-type plasminogen activator (tPA), and urokinase. The somatomedin B domain of vitronectin (SMBD) did not affect SI for any proteinase or k(lim) for tPA but decreased the k(lim) for beta-trypsin. In contrast to SMBD, monoclonal antibodies MA-55F4C12 and MA-33H1F7, the epitopes of which are located at the opposite side of alphaHF, decreased k(lim) and increased SI for every enzyme. These effects were enhanced in the presence of SMBD. RCL insertion for beta-trypsin and tPA is limited by different subsequent steps of PAI-1 mechanism as follows: enzyme acylation and formation of a loop-displaced acyl complex (LDA), respectively. Stabilization of LDA through the disruption of the exosite interactions between PAI-1 and tPA induced an increase in the k(lim) but did not affect the SI. Thus it is unlikely that LDA contributes significantly to the outcome of the serpin reaction. These results demonstrate that the rate of RCL insertion is not necessarily correlated with SI and indicate that an intermediate, different from LDA, which forms during the late steps of PAI-1 mechanism, and could be stabilized by ligands specific to alphaHF, controls bifurcation between the inhibitory and the substrate pathways.

Highlights

  • Serpin [1] plasminogen activator inhibitor-1 (PAI-1),2 the major endogenous inhibitor of tissue- and urokinase-type plasminogen activators [2,3,4,5] is a well characterized thrombotic risk factor

  • Under conditions when the pattern of the exosite interactions between PAI-1 and type plasminogen activator (tPA) is disrupted [51], reactive center loop (RCL) insertion becomes limited by a step of the mechanism, which is different from loop-displaced acyl complex (LDA) formation

  • In contrast to uPA and ␤-trypsin, somatomedin B domain of vitronectin (SMBD) does not affect the klim for tPA, which has the highest number of exosite interactions with PAI-1 (Fig. 2B)

Read more

Summary

Introduction

Serpin [1] plasminogen activator inhibitor-1 (PAI-1),2 the major endogenous inhibitor of tissue- (tPA) and urokinase-type (uPA) plasminogen activators [2,3,4,5] is a well characterized thrombotic risk factor. The SI was calculated as an average of 3–5 measurements Ϯ S.E. SMBD Affects Differently the Kinetics of RCL Insertion for Reactions of NBD P9 PAI-1 with tPA and ␤-Trypsin—The effects of recombinant SMBD and human plasma Vn on the reactions of PAI-1 with ␤-trypsin and tPA were studied in order to determine what step of the reaction (Scheme 1) is affected by the ligands, and to elucidate the mechanism of modulation of PAI-1 activity, as well as to determine contribution of SMBD to the effects of whole Vn. The insertion of RCL, which is the central event of the reaction between PAI-1 and proteinase

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call